Childhood solid tumours
Gene: HRAS
As discussed at the Genomics Cancer Panel Workshop, 16th July 2019: the group agreed that RASopathy associated genes associated with cancer will be included in this panel and that there is enough evidence to rate this gene green.Created: 2 Aug 2019, 11:03 a.m. | Last Modified: 2 Aug 2019, 11:03 a.m.
Panel Version: 1.27
Predisposition to cancer.Created: 2 Aug 2019, 11:03 a.m. | Last Modified: 2 Aug 2019, 11:03 a.m.
Panel Version: 1.27
Publications
Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown
Phenotypes
Costello syndrome
Comment on list classification: Costello syndrome has an elevated risk of tumour in childhoodCreated: 7 Mar 2016, 11:32 p.m.
Costello syndrome has an elevated risk of tumour in childhoodCreated: 7 Mar 2016, 11:13 p.m.
Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Phenotypes
218040
Publications
Comment on list classification: Rasopathy gene; not generally associated with malignancy.Created: 14 Feb 2016, 5:19 p.m.
Source NHS GMS was added to HRAS. Mode of inheritance for gene HRAS was changed from MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted to MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown Added phenotypes Costello syndrome for gene: HRAS Publications for gene HRAS were changed from to 23875798
Source Expert List was added to HRAS. Rating Changed from Green List (high evidence) to Green List (high evidence)
Mode of inheritance for HRAS was changed to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Phenotypes for HRAS were set to Costello syndrome, 218040
This gene has been classified as Green List (High Evidence).
This gene has been classified as Red List (Low Evidence).
HRAS was added to Paediatric congenital malformation-dysmorphism-tumour syndromes panel. Sources: UKGTN
HRAS was added to Paediatric congenital malformation-dysmorphism-tumour syndromes panel. Sources: Emory Genetics Laboratory
HRAS was added to Paediatric congenital malformation-dysmorphism-tumour syndromes panel. Sources: Radboud University Medical Center, Nijmegen